Abstract
Atrial Fibrillation (AF) is the most common cardiac rhythm disorder. It is associated with increased hospitalization, risk of heart failure, and risk of stroke. Once on AF, it can sometimes be difficult to revert to sinus rhythm (SR), potentially requiring pharmacological or electrical cardioversion. Earlier warning of an imminent switch from SR to AF, even if by only a few minutes, could prompt patients to take actions (e.g., taking oral antiarrhythmic drugs) to avoid AF and its associated complications, thereby easing the workload and costs to the health system. The question is whether there is information, even if subtle, in the minutes prior to AF to indicate an imminent switch from SR. This paper shows that, for the vast majority of patients, the answer is affirmative. We propose a deep-learning model that predicts the onset of AF on average 30.8 minutes before it appears, with an accuracy of 83% and an F1-score of 85% on the test data. Moreover, this performance was obtained from R-to-R interval signals, which can be obtained from common wearable devices such as smartwatches and smart bands. The predictions were performed using a deep convolutional neural network, trained and cross-validated on 24-hour data obtained from Holter electrocardiogram recordings of 280 patients, with an additional 70 patients used as test data. We further tested the model with data from two other external centers with 33 patients. Overall, the proposed method has low computational time and could be embedded in smartphones connected to wearable devices that capture RRI for continuous heart monitoring and early warning of AF onset.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Luxembourg National Research Fund (FNR) through PRIDE15/10907093/CriTiCS, and the National Natural Science Foundation of China under grants 92167201 and 82100531.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study design was evaluated and exempted from a full review by the Huazhong University of Science and Technology Institutional Review Board (approval number: TJ-IRB20220423), and approved by the Ethics Review Panel of the University of Luxembourg (approval number: ERP 22-057 RTMonitor). All data have been obtained according to the principles of the declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.